Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.
Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
- Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
- TORONTO, July 24, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D. to its scientific advisory board (SAB).
- Chakraborty and Nicholson join the SAB," said Brent Stead, Ph.D., MBA, CEO of Specific "Their expertise will be incredibly valuable as we advance our Dualase® gene editors toward the clinic.
- "The Specific team is tackling areas of acute medical need where Dualase gene editors would be well differentiated from existing treatments."